Hemangioma, which used to be called a 'strawberry mark', is a benign tumor of the cells lining the blood vessels. In the West, 4 to 10% of infants have at least one hemangioma: 60% are the head or neck, 25% on the chest and 15% on the limbs. A pediatric oral solution of beta-blockers jointly developed by Fabre Dermatologie, the University Hospital Center and the University of Bordeaux recently showed positive results during Phase III of world study When the treatment was given to infants, it completely, or almost completely cured the hemangioma in most of the infants, unlike the almost total lack of effect of the placebo.
Given the results, the Pierre Fabre Dermatologie laboratories and Maruho, a Japanese company, have just announced a mutual agreement for an exclusive license. Contract terms provide for the development of the oral pediatric solution in Japan. In the land of the rising sun, there is no therapy for infantile hemangioma. The agreement meets an unmet medical need for patients afflicted with the benign tumor.
Aside from this success, it should be pointed out that the agreement is also the outcome of a model technology transfer. After Dr. Christine Léauté-Labrèze discovered the advantage of propranolol for treating infantile hemangioma in 2007, Aquitaine Science Transfert , then Aquitaine Valo, provided support to the dermatology team at the Bordeaux University Hospital Center for the study of patentability and patent filing. The patent has now been delivered in Europe, the United States and nine other countries.
 Aquitaine Science Transfert is the Society for the Acceleration of Technology Transfer of the Aquitaine Region (SATT Aquitaine). Created under the Avenir Investment program, its purpose is to enhance academic research and improve technology transfers to business.